SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Inhibition of oncogenic transcriptional programs is a promising therapeutic strategy. A substituted tricyclic benzimidazole, SEL120-34A, is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8), which regulates transcription by associating with the Mediator complex. X-ray crystallography has shown S...

Descripción completa

Detalles Bibliográficos
Autores principales: Rzymski, Tomasz, Mikula, Michał, Żyłkiewicz, Eliza, Dreas, Agnieszka, Wiklik, Katarzyna, Gołas, Aniela, Wójcik, Katarzyna, Masiejczyk, Magdalena, Wróbel, Anna, Dolata, Izabela, Kitlińska, Agata, Statkiewicz, Małgorzata, Kuklinska, Urszula, Goryca, Krzysztof, Sapała, Łukasz, Grochowska, Aleksandra, Cabaj, Aleksandra, Szajewska-Skuta, Małgorzata, Gabor-Worwa, Ewelina, Kucwaj, Katarzyna, Białas, Arkadiusz, Radzimierski, Adam, Combik, Michał, Woyciechowski, Jakub, Mikulski, Maciej, Windak, Renata, Ostrowski, Jerzy, Brzózka, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464911/
https://www.ncbi.nlm.nih.gov/pubmed/28422713
http://dx.doi.org/10.18632/oncotarget.16810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464911/
https://www.ncbi.nlm.nih.gov/pubmed/28422713
http://dx.doi.org/10.18632/oncotarget.16810

Ejemplares similares